spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Electroencephalogram 

 HSMN NewsFeed - 23 Sep 2022
iSyncWave EEG Scanner Receives FDA 510k Clearance
Devices Neurology FDA
 HSMN NewsFeed - 29 May 2018
Zeto Announces First Dry Electrode, Wireless EEG Headset Approved by FDA for Clinical Use
Devices Monitoring Neurology FDA
 HSMN NewsFeed - 15 May 2018
BrainQ Technologies Raises $8.8 Million to Treat Neurodisorders With Artificial Intelligence
Devices Neurology Venture Capital
 HSMN NewsFeed - 10 Aug 2017
NeoSync Secures $13 Million in Financing with Valiance Life Science Investments and Current Investors
Devices Neurology Venture Capital
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 3 Nov 2010
Study in NEJM Shows Novartis Drug Afinitor(R) Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2010
Masimo Acquires SEDLine and Enters the Brain Function Monitoring Market
Devices Monitoring Mergers & Acquisitions
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2010
FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jul 2009
Aspect Medical Systems and LiDCO Group Sign Exclusive U.S. Distribution and Licensing Agreement
Devices Licensing Distribution Monitoring
 HSMN NewsFeed - 1 Jun 2009
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Astro-Med's Grass Technologies Group Receives FDA Clearance to Market Its Neurotrac(R) III Neuromonitoring System
Devices Monitoring Neurology FDA
 HSMN NewsFeed - 27 Jun 2007
Aspect Medical Systems Receives FDA Clearance for BIS View(TM) Monitoring System
Devices Monitoring FDA
 HSMN NewsFeed - 22 May 2006
Aspect Antidepressant Response Index Accurately Predicts Patient Response to SSRI's after One Week on Medication
Devices
Return to NewsFeed  

 Additional items found! 26

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 26 additional stories matching:
Electroencephalogram
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!